DoW Duchenne Muscular Dystrophy, Idea Development Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 17, 2026
- Amount
- Program total $2.5M
- Closes
- Sep 18, 2026 (in 2 days)
Similar opportunities open now
- DoW Duchenne Muscular Dystrophy, Clinical/Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 2 days
- DoW Tick-Borne Disease Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 36 days
- DoW Bone Marrow Failure, Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 49 days
- DoW Rare Cancers Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 63 days
- DoW Kidney Cancer, Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 12 days
Classification and identifiers
- Solicitation number
- HT942526DMDRPIDA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $2.5M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory indiv...